151. Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care.
- Author
-
Alontaga AY, Cano P, Ozakinci H, Puskas JA, Stewart PA, Welsh EA, Yoder SJ, Hicks JK, Saltos AN, Bossler AD, Haura EB, Koomen JM, and Boyle TA
- Subjects
- Humans, Reproducibility of Results, Neoplasms genetics, Gene Expression Profiling methods, Biomarkers, Tumor genetics, Gene Dosage, High-Throughput Nucleotide Sequencing methods
- Abstract
This study describes the validation of a clinical RNA expression panel with evaluation of concordance between gene copy gain by a next-generation sequencing (NGS) assay and high gene expression by an RNA expression panel. The RNA Salah Targeted Expression Panel (RNA STEP) was designed with input from oncologists to include 204 genes with utility for clinical trial prescreening and therapy selection. RNA STEP was validated with the nanoString platform using remnant formalin-fixed, paraffin-embedded-derived RNA from 102 patients previously tested with a validated clinical NGS panel. The repeatability, reproducibility, and concordance of RNA STEP results with NGS results were evaluated. RNA STEP demonstrated high repeatability and reproducibility, with excellent correlation (r > 0.97, P < 0.0001) for all comparisons. Comparison of RNA STEP high gene expression (log2 ratio ≥ 2) versus NGS DNA-based gene copy number gain (copies ≥ 5) for 38 mutually covered genes revealed an accuracy of 93.0% with a positive percentage agreement of 69.4% and negative percentage agreement of 93.8%. Moderate correlation was observed between platforms (r = 0.53, P < 0.0001). Concordance between high gene expression and gene copy number gain varied by specific gene, and some genes had higher accuracy between assays. Clinical implementation of RNA STEP provides gene expression data complementary to NGS and offers a tool for prescreening patients for clinical trials., Competing Interests: Disclosure Statement T.A.B. and J.M.K. have a contract with Bristol Myers Squibb unrelated to this research. E.B.H. consults for Revolution Medicines, Janssen, Ellipses Pharma, Amgen, Kanaph Therapeutics, and ORI Capital, and holds a patent for protein-protein interactions as biomarkers; and research funding from Janssen, Novartis, Revolution Medicines, AstraZeneca, Spectrum Pharmaceuticals, and Genentech, all unrelated to this research. A.N.S. has clinical trial funding to his institution from AstraZeneca, BioAtla, Daiichi Sankyo, Eli Lily, Genentech, Genmab, Memgen, Mersana, Novartis, and Turning Point Therapeutics; and has participated in advisory boards for Daiichi Sankyo, Eli Lilly, and Zymeworks, all unrelated to this research., (Copyright © 2024 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF